Dave Fornell, DAIC Editor

Dave Fornell, Editor DAIC

Blog | Dave Fornell, DAIC Editor | April 08, 2014

Key News and Technology at ACC.14

By Dave Fornell

The biggest news item from the American College of Cardiology (ACC) 63rd Annual Scientific Session was that a transcatheter aortic valve had 26 percent better survival in high-risk patients than surgical valve replacement. This is a big deal, as it shows the promise of transcatheter valve technology to eventually replace open-heart surgical procedures is not a theory out in left field. What is more impressive is the fact that the operators were given three patients to learn how to use the CoreValve device before their fourth and subsequent patients counted in the trial. Despite the relative inexperience with the device and procedure compared to cardiac surgeons, who in most cases have been performing valve replacements for a decade or longer, the fact that the new device outperformed surgery is very impressive. Read more on the trial or watch a video interview with one of the lead investigators.

The major disappointment at ACC.14 was the presentation of the SYMPLICITY HTN-3 renal denervation U.S. pivotal trial. The device used failed to reduce blood pressure a statistically significant amount over a sham procedure, calling into question the future of denervation technology. This session was packed solid with thousands of attendees, who wanted to hear the details and what the future might be for this technology. Read more on the trial or watch a video interview with one of the investigators.

A key late-breaking presentation for cardiac imaging was a combination of five trials that show coronary artery calcium scoring provides an early indication of a patient’s long-term risk for heart disease. Read more on the trial.

A key presentation in electrophysiology was the long-term results from the MADIT-CRT trial, which showed greatly improved outcomes and survival in heart failure patients with left bundle branch block. Read more on the trial.

I walked the exposition show floor and found several new, innovative technologies and on display. I also found some technologies that highlight trends in cardiology, including examples of how to achieve patient engagement and enterprise imaging. Watch the video “DAIC Editor’s Choice for Most Innovative New Technology.”

Related Content

Ancora Heart Enrolls First Patient in European Multi-center Study of AccuCinch Heart Failure Therapy
News | Heart Failure | August 14, 2019
Ancora Heart Inc. announced the first patient was enrolled in the CorCinch EU study, a European multi-center clinical...
Procyrion Receives FDA Breakthrough Device Designation for Aortix System
Technology | Heart Failure | July 30, 2019
Procyrion Inc. secured Breakthrough Device designation by the U.S. Food and Drug Administration (FDA) for its Aortix...
American Heart Association Introduces New Post-acute Care Heart Failure Certification
News | Heart Failure | July 03, 2019
The new Post-Acute Care Heart Failure Certification offered from the American Heart Association (AHA) provides...
Novel Therapeutic Approach Effective at Reducing Pressure for Heart Failure Patients

Image courtesy of Kapur N.K., Karas R.H., Burkhoff D., et al.

News | Heart Failure | June 17, 2019
Results from a first-in-man proof of concept study found occlusion of the superior vena cava (SVC) rapidly and...
Tafamidis meglumine (Vyndaqel) is one of two new drugs cleared by the FDA for the treatment of the cardiomyopathy caused by transthyretin mediated amyloidosis (ATTR-CM) in adults. These are the first FDA-approved treatments for ATTR-CM. U.S. Food and Drug Administration (FDA) approved tafamidis meglumine (Vyndaqel) and tafamidis (Vyndamax) capsules for the treatment of the cardiomyopathy.

Tafamidis meglumine (Vyndaqel) is one of two new drugs cleared by the FDA for the treatment of the cardiomyopathy caused by transthyretin mediated amyloidosis (ATTR-CM) in adults. These are the first FDA-approved treatments for ATTR-CM. 

Technology | Heart Failure | May 06, 2019
May 6, 2019 — The U.S.
The Aortic intra-aortic axial flow pump is designed to unload the heart and increase renal perfusion in heart failure patients experiencing cardiorenal syndrome.

The Aortic intra-aortic axial flow pump is designed to unload the heart and increase renal perfusion in heart failure patients experiencing cardiorenal syndrome.

Feature | Heart Failure | April 29, 2019 | Will Clifton, M.D.
The heart and kidneys are inextricably linked through a diverse web of hemodynamic, neural and hormonal mechanisms.
Diabetes Drug May Reverse Heart Failure
News | Heart Failure | April 19, 2019
Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated that the recently developed antidiabetic...
Diabetes Drug Effective Against Heart Failure in Wide Spectrum of Patients
News | Heart Failure | March 29, 2019
The cardiovascular benefits of the diabetes drug dapagliflozin extend across a wide spectrum of patients and are...
New data from a four-week extension of the landmark PIONEER-HF Trial showed the drug sacubitril/valsartan (Entresto) continued to deliver reductions in the heart failure biomarker N-terminal pro–B-type natriuretic peptide (NT-proBNP), an established biomarker for heart failure severity and prognosis.[1] The data was presented as a late-breaker at the American College of Cardiology (ACC) 2019 Annual Scientific Session in March.
News | Heart Failure | March 27, 2019
March 27, 2019 —New data from a four-week extension of the landmark PIONEER-HF Trial showed the drug sacubitril/valsa
Overlay Init